Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Expenditures (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Capital Expenditures for 15 consecutive years, with $159000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 93.82% year-over-year to $159000.0, compared with a TTM value of $20.3 million through Dec 2025, up 549.78%, and an annual FY2025 reading of $22.7 million, up 439.71% over the prior year.
  • Capital Expenditures was $159000.0 for Q4 2025 at Arrowhead Pharmaceuticals, down from $22.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $109.9 million in Q2 2024 and bottomed at -$113.0 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $5.7 million, with a median of $5.3 million recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 948.65% in 2023, while the deepest fall reached 402.0% in 2023.
  • Year by year, Capital Expenditures stood at $5.8 million in 2021, then skyrocketed by 143.06% to $14.0 million in 2022, then decreased by 19.61% to $11.3 million in 2023, then tumbled by 77.2% to $2.6 million in 2024, then crashed by 93.82% to $159000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ARWR at $159000.0 in Q4 2025, $22.4 million in Q3 2025, and -$12000.0 in Q2 2025.